Beauty Farm Medical and Health Industry Inc. (Beauty Farm Medical) repurchased 40,000 ordinary shares on 21 September 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on 21 September 2026.

The on-market transaction, conducted under the company’s existing buy-back mandate granted on 26 June 2026, was executed within a price range of HK$18.93 to HK$19.32 per share, translating into a volume-weighted average repurchase price of HK$19.2196. The aggregate consideration amounted to HK$0.77 million.

Post-transaction, Beauty Farm Medical’s treasury share holding increased to 3.77 million shares, while the number of issued shares (excluding treasury shares) declined to 247.82 million from 247.86 million—a marginal 0.016 % reduction. Total issued shares, inclusive of treasury stock, remained unchanged at 251.59 million.

Since the approval of the June mandate, the company has repurchased 700,500 shares, representing 0.28 % of the 248.52 million shares in issue when the mandate was granted. The firm is authorised to buy back up to 24.85 million shares under this mandate.

Under Hong Kong Listing Rules, Beauty Farm Medical is subject to a 30-day moratorium—ending 21 October 2026—during which it cannot issue new shares or dispose of treasury shares without prior Exchange approval.